Tag: European Commission (EC)

April 7, 2022 Off

Sanofi’s Dupixent Now Available for Children Aged 6 to 11 Years with Severe Asthma with Type 2 Inflammation

By Author

The European Commission (EC) has expanded the marketing authorization for Sanofi’s Dupixent (dupilumab) in the European Union to include treatment of children aged 6 to 11 years as an add-on maintenance treatment for uncontrolled severe asthma.

June 9, 2017 Off

J&J receives final EC approval to acquire Actelion

By Dino Mustafić

Johnson & Johnson has announced that, with today’s receipt of approval of the proposed acquisition of Actelion from the European Commission (EC), all regulatory approvals required to complete the transaction have been received.